BioTrinity 2012 - European Biopartnering and Investment Conference - April 24 -26

Where Great Minds and Smart Money meet Under One Roof

Record Partnering Activity! 800 delegates and rising ... Online Registration Now CLOSED

BioTrinity is the premier European Biopartnering and Investment Conference, partnering R&D companies with big pharma and more biomedical investors than any other European partnering conference. Check out who else is coming, including over 70 investment firms confirmed, and what they say about BioTrinity, the expert discussion panels, and which more than 70 companies will be presenting in the showcase. Don't miss out: 

 Meet the key licensing contacts from big pharma including Abbott, Amgen, Astellas, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Genzyme, GSK, Goldshield Group, Merck & Co., Novartis, Shire, Takeda, Teijin and Teva and other senior BD&L execs

 Meet 100 delegates from active VC and Corporate Venture firms including MedImmune Ventures, SR One, Shire Strategic Investment, Merck Serono Ventures, Merck Research Ventures, Abbott Biotech Ventures, Astellas Venture Management, and Boehringer Ingelheim Ventures and many international VCs

 Meet a hand-picked crop of early-stage companies you haven't seen elsewhere

 Meet the senior execs who can complete the value chain for your business

...Deploying EBD Group's partneringONE®, the industry gold-standard partnering system with entirely private partnering: 

The "Event of the Year" - BioTrinity 2012: Huge partnering potential with global pharma / investors 75 presentations by hand-picked R&D companies Great networking opportunities  First class venue at Newbury Racecourse Exciting Social Programme:  Grand Opening Reception and Gala Dinner  Europe's Largest Investor-only Dinner Projected 2012 Statistics:  800+ delegates  2000 formal one-to-one partnering meetings 80 investment delegates from more than 10 countries  All of the top 20 global pharma 2011 Statistics:  750+ delegates (up 21%) from 20 countries  1700 partnering meetings (up 20%)  75 investment firms from 12 countries  Nearly all of the top 20 global pharma Given its prodigious year-on-year growth, and doubling in size in three years, we believe BioTrinity 2012 will be the biggest and best yet: 850 plus delegates, over 2500 partnering meetings (up 50% again on the previous year), 100 delegates from investment firms and licensing representation from the key global pharma companies.  Remember BioTrinity is the only bioconference in Europe to have grown over 100% over three years of recession - read the testimonials to find out why people are flocking to BioTrinity. Check out the glowing testimonials we received for BioTrinity, and view the photos from the Gallery or watch the video now.